Status:
COMPLETED
IV Iron in Acute Decompensated Heart Failure
Lead Sponsor:
Rambam Health Care Campus
Conditions:
Heart Failure
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
The study aims Compare the effect of addition of IV FERRLECITR (ferric gluconate) to standard therapy to standard therapy alone (without any IV iron treatment) in patients admitted with acute decompen...
Detailed Description
Heart Failure (HF) constitutes one of the biggest burdens on the public health system, with incidence of 20 per 1000 persons above the age of 65 and up to 80 per 1000 persons above 85 years of age. Ac...
Eligibility Criteria
Inclusion
- Patients admitted due to acute decompensated heart failure to internal medicine department H or cardiology department.
- Must meet two of the following criteria :
- NT pro BNP \> 300 pg/ml (\>800 pg/ml in the presence of Atrial Fibrillation).
- Peripheral pitting edema,
- Jugular Venous Distention,
- pulmonary edema/congestion according to physical examination or Chest X-ray.
- IV furosemide treatment on admission to ER or internal ward/cardiology department.
- Hb level 8-14 mg/dl on admission.
- Iron stores: Ferritin \<100 or Ferritin 100-300 and Transferrin saturation \< 20%.
- No evidence of active bleeding.
- Patient provided informed consent.
Exclusion
- Cardiogenic shock or any other condition requiring IV vasopressors.
- Previous allergy or anaphylaxis due to IV Iron.
- Active malignancy undergoing treatment.
- Status post major surgery involving substantial blood loss in the past 3 months.
- Indication for Blood transfusion.
- Infection indicating IV antibiotics.
- History of acquired iron overload; known haemochromatosis or first relatives with hemochromatosis; and allergic disorders (asthma, eczema, and anaphylactic reactions).
- hemolytic anemia.
- History of chronic liver disease and/or alanine transaminase (ALT) or aspartate transaminase (AST) \>3 times the upper limit of the normal range; chronic lung disease; myelodysplastic disorder; and known HIV/AIDS disease.
- Recipient of immunosuppressive therapy or renal dialysis. History of erythropoietin, IV iron therapy, and blood transfusion in previous 30 days.
- Unstable angina pectoris, as judged by the investigator; severe uncorrected valvular disease or left ventricular outflow obstruction; obstructive cardiomyopathy; uncontrolled fast atrial fibrillation or flutter (heart rate \>110 beats per minute \[bpm\]); uncontrolled symptomatic brady- or tachyarrhythmias.
- Musculoskeletal limitation that, in the judgement of the investigator, would impair cardiopulmonary exercise testing.
- Pregnant or breastfeeding.
- Inability to comprehend study protocol.
- Parallel participation in another clinical trial.
Key Trial Info
Start Date :
September 1 2019
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 31 2021
Estimated Enrollment :
34 Patients enrolled
Trial Details
Trial ID
NCT04063033
Start Date
September 1 2019
End Date
December 31 2021
Last Update
April 11 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Rambam Medical Center
Haifa, Israel